sur ALT5 Sigma Corp
ALT5 Sigma Unveils 2024 AGM Results and Strategic Spin-off Plans
ALT5 Sigma Corporation announced the approval of all resolutions at its 2024 Annual General Meeting. The fintech firm, noted for its blockchain-driven solutions, witnessed the re-election of major board members and the election of CEO Peter Tassiopoulos to the board. ALT5 Sigma highlighted its record transaction volumes for 2024, driven in part by growth in its ALT5 Pay and ALT5 Prime platforms.
The company plans to spin off its healthcare assets into Alyea Therapeutics Corporation in 2025. Alyea's independent focus will enhance its strategic capabilities in developing non-addictive pain management solutions. Alyea intends to acquire Soin Bioscience LLC, strengthening its position in the pain relief market.
Vay Tham, ALT5’s Chief Revenue Officer, emphasized continued innovation and expansion in fintech services, anticipating further success in 2025. Discussions on private financing for Alyea are ongoing to address the financial strategy for the spin-off.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ALT5 Sigma Corp